Drug Use Investigation for AMERGE (Naratriptan Hydrochloride) Tablet

Drug Use Investigation for AMERGE (Naratriptan Hydrochloride) Tablet

The study is designed to investigate the information on safety and efficacy of naratriptan tablets on Japanese subjects with migraine headache during Japanese post-marketing surveillance period.

Inclusion Criteria:

• Subjects with migraine headache
• Must use naratriptan tablets for the first time

Exclusion Criteria:

• Subjects with hypersensitivity to naratriptan
• Subjects with history, symptoms, or signs of myocardial infarction, ischemic cardiac disease, or variant angina
• Subjects with history of peripheral vascular disorder
• Subjects with history of cerebrovascular disorder or transient ischemic attacks
• Subjects with uncontrolled high-blood pressure
• Subjects with severe hepatic function disorder or renal function disorder
• Subjects taking ergotamine, ergotamine derivative containing product, or 5-HT1B/1D agonist